Fludarabine and cytarabine in patients with acute myeloid leukemia refractory to two different courses of front-line chemotherapy

Leukemia Research

Volumn 35, Issue 7, 2011, Pages 885-888

  Mehta, Dhaval R ^a   Foon, Kenneth A ^a   Redner, Robert L ^a   Raptis, Anastasios ^a   Agha, Mounzer ^a   Hou, Jing Zhou ^a   Duggal, Shrina ^a   Luong, The Minh ^a   Schlesselman, James J ^a   Boyiadzis, Michael ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Acute myeloid leukemia; Chemotherapy; Cytarabine; Fludarabine; Prognostic factors

Indexed keywords

CYTARABINE; ETOPOSIDE; FLUDARABINE; IDARUBICIN; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BACTEREMIA; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; DRUG EFFICACY; FEMALE; HUMAN; KARYOTYPE; LEUKEMIA REMISSION; LIVER TOXICITY; LUNG MYCOSIS; MALE; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; CYTARABINE; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; HUMANS; IDARUBICIN; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MITOXANTRONE; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT OUTCOME; VIDARABINE; YOUNG ADULT;

EID: 79958708036     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.12.030     Document Type: Article

References (23)

1. Dohner H., Estey E.H., Amadori S., Appelbaum F.R., Buchner T., Burnett A.K., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net. Blood 2010, 115:453-474.
2. Rowe J.M., Tallman M.S. How I treat acute myeloid leukemia. Blood 2010, 116:3147-3156.
3. Anderlini P., Ghaddar H.M., Smith T.L., Pierce S., Kantarjian H.M., O'Brien S., et al. Factors predicting complete remission and subsequent disease-free survival after a second course of induction therapy in patients with acute myelogenous leukemia resistant to the first. Leukemia 1996, 10:964-969.
4. Jourdan E., Reiffers J., Stoppa A.M., Sotto J.J., Attal M., Bouabdallaha R., et al. Outcome of adult patients with acute myeloid leukemia who failed to achieve complete remission after one course of induction chemotherapy: a report from the BGMT Study Group. Leuk Lymphoma 2001, 42:57-65.
5. McHayleh W., Sehgal R., Redner R.L., Raptis A., Agha M., Natale J., et al. Mitoxantrone and etoposide in patients with newly diagnosed acute myeloid leukemia with persistent leukemia after a course of therapy with cytarabine and idarubicin. Leuk Lymphoma 2009, 50:1848-1853.
6. Mayer R.J., Davis R.B., Schiffer C.A., Berg D.T., Powell B.L., Schulman P., et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994, 331:896-903.
7. Bishop J.F., Matthews J.P., Young G.A., Szer J., Gillett A., Joshua D., et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996, 87:1710-1717.
8. Capizzi R.L. Curative chemotherapy for acute myeloid leukemia: the development of high-dose ara-C from the laboratory to bedside. Invest New Drugs 1996, 14:249-256.
9. Gandhi V., Estey E., Keating M.J., Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 1993, 11:116-124.
10. Estey E., Plunkett W., Gandhi V., Rios M.B., Kantarjian H., Keating M.J. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma 1993, 9:343-350.
11. Estey E., Thall P., Andreeff M., Beran M., Kantarjian H., O'Brien S., et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 1994, 12:671-678.
12. Vidarsson B., Abonour R., Williams E.C., Woodson R.D., Turman N.J., Kim K., et al. Fludarabine and cytarabine as a sequential infusion regimen for treatment of adults with recurrent, refractory or poor prognosis acute leukemia. Leuk Lymphoma 2001, 41:321-331.
13. Slovak M.L., Kopecky K.J., Cassileth P.A., Harrington D.H., Theil K.S., Mohamed A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000, 96:4075-4083.
14. Byrd J.C., Mrozek K., Dodge R.K., Carroll A.J., Edwards C.G., Arthur D.C., et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002, 100:4325-4336.
15. Cheson B.D., Bennett J.M., Kopecky K.J., Buchner T., Willman C.L., Estey E.H., et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003, 21:4642-4649.
16. Biggs J.C., Horowitz M.M., Gale R.P., Ash R.C., Atkinson K., Helbig W., et al. Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood 1992, 80:1090-1093.
17. Fung H.C., Stein A., Slovak M., O'Donnell M.R., Snyder D.S., Cohen S., et al. A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome. Biol Blood Marrow Transplant 2003, 9:766-771.
18. Song K.W., Lipton J. Is it appropriate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia?. Bone Marrow Transplant 2005, 36:183-191.
19. Litzow M.R. Progress and strategies for patients with relapsed and refractory acute myeloid leukemia. Curr Opin Hematol 2007, 14:130-137.
20. Ravandi F., Burnett A.K., Agura E.D., Kantarjian H.M. Progress in the treatment of acute myeloid leukemia. Cancer 2007, 110:1900-1910.
21. Mato A.R., Morgans A., Luger S.M. Novel strategies for relapsed and refractory acute myeloid leukemia. Curr Opin Hematol 2008, 15:108-114.
22. Fathi A.T., Grant S., Karp J.E. Exploiting cellular pathways to develop new treatment strategies for AML. Cancer Treat Rev 2010, 36:142-150.
23. Schlenk R.F., Dohner K., Krauter J., Frohling S., Corbacioglu A., Bullinger L., et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008, 358:1909-1918.